Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001

An Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001

This EAP was designed to provide TJ210001 to the remaining subjects with relapsed or refractory solid tumors who were enrolled on the parent study, TJ210001STM101 (NCT04678921), and plan to continue with treatment.

Study Overview

• Status: No longer available
• Conditions: Solid Tumor Metastatic Cancer Advanced Cancer
• Intervention / Treatment: Drug: TJ210001

• Study Type: Expanded Access
• Expanded Access Type: Individual Patients

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Males or females, of any race, age ≥ 18 years;
2. Participation in the parent TJ210001STM101 study and thought to have potential to derive clinical benefit from continued treatment in the opinion of the parent study investigator from uninterrupted dosing of TJ210001;
3. Willingness and ability to comply study treatment and standard of care testing and procedures;

4. Women of childbearing potential (WOCBP) must:

   1. Agree to use at least 2 effective contraceptive methods (1 highly effective method in combination with a barrier method; oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner), one of which must be barrier, from signing the ICF, throughout the study, and for up to 12 weeks following the last dose of TJ210001;
   2. Avoid conceiving for 12 weeks after the last dose of TJ210001;
   3. Avoid donation of ova until 12 weeks after the last dose of TJ210001;
   4. Agree to ongoing urine pregnancy testing, if clinically indicated, during the course of the study.
5. Males must agree to use a condom (a latex condom is recommended) during sexual contact with a pregnant female or a female of childbearing potential and will avoid donation of sperm or having a female partner conceive from the time of signing the ICF, while participating in the study, during dose interruptions, and for at least 12 weeks after the last dose of study treatment, even if he has undergone a successful vasectomy;
6. Patient or patient's health care proxy is able and willing to provide written informed consent and able to follow study instructions.

Exclusion Criteria:

• Any unresolved ongoing toxicity or clinical event that would make continued treatment with TJ210001 inappropriate; 2. Current treatment on another therapeutic clinical trial; 3. Currently pregnant; 4. Current evidence of any condition (including medical, psychiatric or substance abuse disorder), therapy, or laboratory abnormality that might interfere with the patient's participation or is not in the best interest of the patient to participate, in the opinion of the treating Investigator

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: I-Mab Biopharma Co. Ltd.
• Investigators: Principal Investigator: Laura Feller, NP, Horizon Oncology Center

Study record dates

Study Registration Dates

• First Submitted: August 19, 2022
• First Submitted That Met QC Criteria: August 19, 2022
• First Posted (ACTUAL): August 23, 2022

Study Record Updates

• Last Update Posted (ACTUAL): October 18, 2022
• Last Update Submitted That Met QC Criteria: October 14, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: monoclonal antibody anti-C2aR
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplastic Processes; Neoplasm Metastasis
• Other Study ID Numbers: TJ210001STM103